5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
about
Mesalamine in the treatment and maintenance of remission of ulcerative colitisPreventive health measures in inflammatory bowel diseaseThe Use of a Bayesian Hierarchy to Develop and Validate a Co-Morbidity Score to Predict Mortality for Linked Primary and Secondary Care Data from the NHS in England.Extraintestinal manifestations and complications in inflammatory bowel diseases.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?European evidence-based Consensus on the management of ulcerative colitis: Current management.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.Five-aminosalicylic Acid: an update for the reappraisal of an old drugRenal failure in lithium-treated bipolar disorder: a retrospective cohort study.Guidelines for the management of inflammatory bowel disease in adults.5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.The risks and the benefits of mesalazine as a treatment for ulcerative colitis.Renal effects of long-term treatment with 5-aminosalicylic acidBalsalazide disodium for the treatment of ulcerative colitis.General health maintenance in IBD.Efficacy and safety of drugs for ulcerative colitis.Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.Renal manifestations and complications of inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Conventional drug therapy for inflammatory bowel disease.Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatmentUlcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly.5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis.5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.5-Aminosalicylates and effects on renal function in patients with Crohn's disease.Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization.A validation study of the CirCom comorbidity score in an English cirrhosis population using the Clinical Practice Research Datalink.
P2860
Q26865546-D28A6ABF-A24E-437B-BA74-0AFCA1C2ACB0Q28078112-BC4908F2-1583-490E-A2FD-7DA95C805B3BQ31139441-9151ECD0-925E-42E8-9AB7-8A88AD48E05AQ33866998-C8B7B1E4-82A8-41D2-BA85-7DCB146EF7BBQ33868970-134AF5F3-30F6-400E-A75E-533CD2624214Q34025054-9BD12726-8405-43F6-95BE-8722C289487AQ34273329-8E19CC22-F76E-4F95-A7E4-8485CCBAE547Q34564902-CD7717AF-AF4C-4F8D-A729-C705556A7B4EQ34648896-8A84B19D-4E12-4BB0-A339-4CC13D9859DBQ35061210-A8FF3305-2BD8-4A8B-8CEE-3D0026A3579FQ35132107-DC0D58BE-D190-4169-A5FD-A11B9B815ACAQ35790559-43731C92-DB5D-4A88-A918-20DB4B307073Q36715466-7EC4FCEE-DF19-4D6E-ACAC-B0E6FE845A7BQ36762423-8AF50E28-E036-41EB-AC2C-45C341736129Q37223156-148845C7-CBB9-4906-9ABB-571ADAEEC37BQ37345858-9A4078A7-AF5D-4A78-853B-C20EDA44E493Q37547079-ABAD1D1C-B43A-4217-998A-8DDCFC5670FBQ37727232-1F564653-7DBF-4EA6-AD5F-4670524F0DA1Q37781314-9BDED6EF-E108-4E9A-BBA9-2F59AE652DACQ37789000-A2136F27-5482-42D4-AE60-0D3229C0CA9CQ37827164-7822F1C0-94B7-4D26-AAEA-B9AE1A8F6550Q37892884-3C804E66-0769-4EFD-BAD5-7CC7525E7E53Q38293796-9ACD5441-9EE1-430F-805F-9101D96671CDQ38609002-1126F622-B4D3-422E-BF5D-F4BEB72B1D90Q40171838-2E0659E1-4A61-458D-A55F-3C12582E75B3Q40747451-B2D8D984-E12C-4044-895D-4803860AFA18Q41169995-748AF55C-3D61-48AB-BECD-4015609366C7Q44712153-C1ADEB6D-E26C-489A-9C86-3F4900ED2487Q45917894-0BB2C410-26EB-42B1-9DE8-41C304AD0A24Q46269214-24A70D1F-B078-4140-ABA1-6A76CCFDB9BCQ46766282-24CC0816-2230-419E-A228-FB24FCC26C87Q46956410-BE044C49-88FD-43EB-91B9-76E20C107CEBQ49387323-0FEB020E-D64D-4628-8F15-CBBACD615721
P2860
5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
5-aminosalicylic acids and the ...... e British epidemiologic study.
@en
5-aminosalicylic acids and the ...... e British epidemiologic study.
@nl
type
label
5-aminosalicylic acids and the ...... e British epidemiologic study.
@en
5-aminosalicylic acids and the ...... e British epidemiologic study.
@nl
prefLabel
5-aminosalicylic acids and the ...... e British epidemiologic study.
@en
5-aminosalicylic acids and the ...... e British epidemiologic study.
@nl
P2093
P1433
P1476
5-aminosalicylic acids and the ...... e British epidemiologic study.
@en
P2093
Hubert G M Leufkens
Richard F Logan
Simon Travis
P304
P356
10.1053/J.GASTRO.2004.03.016
P407
P577
2004-06-01T00:00:00Z